Radiotekhnika
Publishing house Radiotekhnika

"Publishing house Radiotekhnika":
scientific and technical literature.
Books and journals of publishing houses: IPRZHR, RS-PRESS, SCIENCE-PRESS


Тел.: +7 (495) 625-9241

 

Investigation of matrix metalloproteinases (mmps) and their tissue inhibitors in patients with cancer and benign diseases of endometrium. Part 1. General mmps characteristics, their role in normal endometrium and endometriosis

Keywords:

N.E. Kushlinskii  Corresponding-Member of RAS, Dr.Sc. (Med), Professor, Heard of the Department of Clinical Bioche-mistry and Laboratory Diagnostics, I.A. Evdokimov Moscow University of Medicine and Dentistry of Ministry of Health of the Russian Federation (Moscow)
E-mail: biochimia@yandex.ru
S.V. Mushtenko  Post-graduate Student, Department of Oncology, I.A. Evdokimov Moscow University of Medicine and Dentistry of Ministry of Health of the Russian Federation (Moscow)
I.V. Tereshkina  Ph.D. (Med.), I.A. Evdokimov Moscow University of Medicine and Dentistry of Ministry of Health of the Russian Federation (Moscow)
V.D. Ermilova  Ph.D. (Med.), Department of Pathological Anatomy of Human Tumors, N.N. Blokhin National Medical Re-search Center of Oncology of Ministry of Health of the Russian Federation (Moscow)
E.S. Gershtein  Dr.Sc. (Biol.), Professor, Clinical Biochemistry Laboratory, N.N. Blokhin National Medical Research Center of Oncology of Ministry of Health of the Russian Federation (Moscow)
N.E. Levchenko  Dr.Sc. (Med.), Professor, Head of Oncogynecology Department, N.N. Blokhin National Medical Research Center of Oncology of Ministry of Health of the Russian Federation (Moscow)


A review of the literature on fundamental and clinical studies of the family of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMP) in the endometrium is presented. Molecular-biological features of MMPs and TIMPs have been cha-racterized in detail in endometriosis and endometrial cancer, as well as the results of targeted therapy of endometrial dis-eases.

References:
  1. Bray F., Jemal A., Grey N., Ferlay J., Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study // Lancet Oncol. 2012. V. 13. № 8. Р. 790801.
  2. Bray F., Ferlay J., Laversanne M., Brewster D.H., Gombe Mbalawa C., Kohler B., Piñe-ros M., Steliarova-Foucher E., Swaminathan R., Antoni S., Soerjomataram I., Forman D. Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration // Int. J. Cancer. 2015. V. 137. № 9. Р. 20602071.
  3. Antoni S., Soerjomataram I., Møller B., Bray F., Ferlay J. An assessment of GLOBOCAN methods for deriving national estimates of cancer incidence // Bull. World Health Organ. 2016. V. 94. № 3. Р. 174–184.
  4. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016 // CA Cancer J. Clin. 2016. V. 66. № 1. Р. 7-30.
  5. Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012 // CA Cancer J. Clin. 2015. V. 65. № 2. Р. 87108.
  6. Dzhemal A., Vineis P., Brej F., Torre L., Forman D. (redakciya). Atlas po onkologii. Izd. 2-e. Atlanta. SHtat Dzhordzhia: Amerikanskoe onkologicheskoe obshchestvo. 2014 г. www.can¬cer.org/canceratlas.
  7. Lortet-Tieulent J., Ferlay J., Bray F., Jemal A. International Patterns and Trends in Endometrial Cancer Incidence, 1978-2013 // J. Natl. Cancer. Inst. 2017 Oct 16. doi: 10.1093/jnci/djx214. [Epub ahead of print].
  8. Hachisuga T. Aging and uterine serous carcinoma // Histol. Histopathol. 2018 Mar 22:11985. doi: 10.14670/HH-11-985. [Epub ahead of print].
  9. Klinicheskaya onkoginekologiya: Rukovodstvo dlya vrachej / Pod red. V.P. Kozachenko. Izd. 2-e, pererab. i dop. M.: «Izdatel'stvo Binom». 2016. 426 s.
  10. Koutoukidis D.A., Lopes S., Atkins L., Croker H., Knobf M.T., Lanceley A., Beeken R.J. Use of intervention mapping to adapt a health behavior change intervention for en-dometrial cancer survivors: the shape-up following cancer treatment program // BMC Public Health. 2018. V. 18. № 1. Р. 415. doi: 10.1186/s12889-018-5329-5.
  11. Onkologiya. Klinicheskie rekomendacii / Pod red. akad. RAN M.I. Davydova. M. Izdatel'skaya gruppa RONC. 2015. 680 s.
  12. Gulyaeva L.F., Kushlinskij N.E. Geneticheskie i ehpigeneticheskie aspekty gormonal'nogo kancerogeneza. Novosibirsk: IPC NGU. 2017. 114 s.
  13. Bohman YA.V. Lekcii po onkoginekologii. M.: OOO «Medicinskoe Informacionnoe Agenstvo». 2007. 304 s.
  14. Sacerdote C., Ricceri F. Epidemiological dimensions of the association between type 2 diabetes and cancer: a review of observational studies // Diabetes Res. Clin. Pract. 2018 Mar 26. pii: S0168-8227(18)30202-X. doi: 10.1016/j.diab¬res.2018.03.002. [Epub ahead of print]
  15. Dong M., Jiang S., Tian W., Yan Y., Gao C., Gao J., Sheng Y., Wang Y., Xue F. Preliminary clinical application of an aromatase inhibitor and a gonadotropin-releasing hormone agonist combination for inoperable endometrial cancer patients with comorbid-ities: case report and literature review // Cancer Biol. Ther. 2018 Mar 27:0. doi: 10.1080/15384047.2018.1456609. [Epub ahead of print].
  16. Pal N., Broaddus R.R., Urbauer D.L., Balakrishnan N., Milbourne A., Schmeler K.M., Meyer L.A., Soliman P.T., Lu K.H., Ramirez P.T., Ramondetta L., Bodurka D.C., Wes-tin S.N. Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device // Obstet. Gynecol. 2018. V. 131. № 1. Р. 109–116.
  17. Sahoo S.S., Lombard J.M., Ius Y., O'Sullivan R., Wood L.G., Nahar P., Jaaback K., Tanwar P.S. Adipose-Derived VEGF-mTOR Signaling Promotes Endometrial Hyperplasia and Cancer: Implications for Obese Women // Mol. Cancer Res. 2018. V. 16. № 2. Р. 309–321.
  18. Dhami J., Hirshfield K.M., Ganesan S., Hellmann M., Rojas V., Amorosa J.K., Riedlin-ger G.M., Zhong H., Ali S.M., Pavlick D., Elvin J.A., Rodriguez-Rodriguez L. Comprehensive Genomic Profiling Aids in Treatment of a Metastatic Endometrial Cancer // Cold Spring Harb. Mol. Case Stud. 2018 Mar 27. pii: mcs.a002089. doi: 10.1101/mcs.a002089. [Epub ahead of print].
  19. Banno K., Yanokura M., Iida M., Masuda K., Aoki D. Carcinogenic mechanisms of endometrial cancer: involvement of genetics and epigenetics // J. Obstet. Gynaecol. Res. 2014. V. 40. № 8. Р. 1957–1967.
  20. Proctor L., Pradhan M., Leung S., Cheng A., Lee C.H., Soslow R.A., Gilks C.B., Talhouk A., McAlpine J.M., Danielsen H.E., Hoang L.N. Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer // Gynecol. Oncol. 2017. V. 146. № 3. Р. 596–602.
  21. Kushlinskij N.E., Nemcova M.V. Molekulyarno-biologicheskie harakteristiki zlokachestvennyh novoobrazovanij. V kn.: «Biologicheskie markery opuholej: fundamental'nye i klinicheskie issledovaniya» / Pod red. N.E. Kush¬linskogo i M.A. Krasil'nikova. M.: Izd-vo RAMN. 2017. S. 20–65.
  22. Kushlinskij N.E., Krasil'nikov M.A. Biologicheskie markery opuholej: fundamental'nye i klinicheskie issledovaniya. M.: Izd-vo RAMN. 2017. 632 s.
  23. Gershtejn E.S., Kushlinskij N.E. Sovremennye predstavleniya o mekhanizmah peredachi signalov faktorov rosta kak osnova ehffektivnoj molekulyarno-napravlennoj protivoopuholevoj terapii // Voprosy biologicheskoj, medicinskoj i farmacevticheskoj himii. 2007. № 1. S. 4–9.
  24. Hanahan D., Weinberg R.A. The hallmarks of cancer: the next generation // Cell. 2011. V. 144. № 5. Р. 646–674.
  25. Kushlinskij N.E., Gershtejn E.S. Issledovanie matriksnyh metalloproteinaz i ih tkanevyh ingibitorov v opuholyah i perifericheskoj krovi onkologicheskih bol'nyh. Klinicheskie perspektivy // Laboratornaya sluzhba. 2013. T. 2. № 1. S. 25–38.
  26. Kushlinskij N.E., Gershtejn E.S. Matriksnye metalloproteinazy i komponenty sistemy aktivacii plazminogena v patogeneze i klinicheskoj techenii raka tolstoj kishki // Patogenez. 2013. T. 11. № 3. S. 4–12.
  27. Gershtejn E.S., Kushlinskij N.E. Klinicheskie perspektivy issledovaniya associirovannyh s opuhol'yu proteaz i ih tkanevyh ingibitorov u onkologicheskih bol'nyh // Vestnik Rossijskoj akademii medicinskih nauk. 2013. № 5. S. 16–27.
  28. Deryugina E.I. Quigley J.P. Pleiotropic roles of matrix metalloproteinases in tumor an-gioge¬ne¬sis: contrasting, overlapping and compensatory functions // Biochim. Biophys. Acta. 2010. V. 1803. № 1. С. 103–120.
  29. Shadrina A.S., Plieva YA.Z., Kushlinskij D.N., Morozov A.P., Filipenko M.L. Klassifikaciya, regulyaciya aktivnosti, geneticheskij polimorfizm matriksnyh metalloproteinaz v norme i pri patologii // Al'manah klinicheskoj mediciny. 2017. T. 45. № 4. S. 266–279.
  30. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression // Nat. Rev. Cancer. 2002. V. 2. № 3. P. 161–174.
  31. Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry // Circ. Res. 2003. V. 92. № 8. Р. 827–839.
  32. Graesslin O., Cortez A., Uzan C., Birembaut P., Quereux C., Darai E. Endometrial tumor invasiveness is related to metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expressions // Int. J. Gynecol. Cancer. 2006. V. 16. № 5. Р. 1911–1917.
  33. Graesslin O., Cortez A., Fauvet R., Lorenzato M., Birembaut P., Darai E. Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expression in normal, hyperplastic and neoplastic endometrium: a clinical-pathological correlation study // Ann. Oncol. 2006a. V. 17. № 4. Р. 637–645.
  34. Page-McCaw A., Ewald A.J., Werb Z. Matrix metalloproteinases and the regulation of tissue remodeling // Nat. Rev. Mol. Cell Biol. 2007. V. 8. № 3. Р. 221–233.
  35. Raffetto J.D., Khalil R.A. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease // Biochem. Pharmacol. 2008. № 75. Р. 346–359.
  36. Nagase H., Visse R., Murphy G. Structure and function of matrix metalloproteinases and TIMPs // Cardiovasc. Res. 2006. V. 69. № 3. Р. 562–573.
  37. Verma R.P., Hansch C. Matrix metalloproteinases (MMPs): Chemical-biological functions and (Q)SARs // Bioorg. Med. Chem. 2007. № 15. Р. 2223–2268.
  38. Westermarck J., Kahari V.M. Regulation of matrix metalloproteinase expression in tumor invasion // FASEB J. 1999. V. 13. № 8. Р. 781–792.
  39. Malemud C.J. Matrix metalloproteinases (MMPs) in health and disease: an overview // Front Biosci. 2006. № 11. Р. 1696–1701.
  40. Li J., Wang J.M., Liu Y.H., Zhang Z., Han N., Wang J.Y., Xue S.H., Wang P. Effect of microRNA-106b on the invasion and proliferation of trophoblasts through targeting MMP-2 // Zhonghua Fu Chan Ke Za Zhi. 2017. V. 52. № 5. Р. 327–332.2.
  41. Yang L., Song X., Zhu J., Li M., Ji Y., Wu F., Chen Y., Cui X., Hu J., Wang L., Cao Y., Wei Y., Zhang W., Li F. Tumor suppressor microRNA-34a inhibits cell migration and invasion by targeting MMP-2/MMP-9/FNDC3B in esophageal squamous cell carcinoma. Int. J. Oncol. 2017;51(1):378–388.
  42. Yan C., Boyd D.D. Regulation of matrix metalloproteinase gene expression // J. Cell. Physiol. 2007. V. 211. № 1. Р. 19–26.
  43. Chen Q., Jin M., Yang F., Zhu J., Xiao Q., Zhang L. Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediators Inflamm. 2013. № 2013. Р. 928315. doi:10.1155/2013/928315.
  44. Chase A.J., Newby A.C. Regulation of matrix metalloproteinase (matrixin) genes in blood vessels: a multi-step recruitment model for pathological remodeling // J. Vasc. Res. 2003. V. 40. № 4. Р. 329–343.
  45. Wang F.Q., So J., Reierstad S., Fishman D.A. Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase // Int. J. Cancer. 2005. V. 114. № 1. Р. 19–31.
  46. Määttä M., Soini Y., Liakka A., Autio-Harmainen H. Localization of MT1-MMP, TIMP-1, TIMP-2, and TIMP-3 messenger RNA in normal, hyperplastic, and neoplastic endometrium. Enhanced expression by endometrial adenocarcinomas is associated with low differentiation // Am. J. Clin. Pathol. 2000. V. 114. № 3. Р. 402–411.
  47. Cieplak P., Strongin A.Y. Matrix metalloproteinases – from the cleavage data to the prediction tools and beyond // Biochim. Biophys. Acta. 2017; pii: S0167-4889(17)30064-2. doi: 10.1016/j.bbamcr.2017.03.010. [Epub ahead of print].
  48. Levin M., Udi Y., Solomonov I., Sagi I. Next Generation Matrix Metalloproteinase Inhibitors   Novel Strategies Bring New Prospects // Biochim. Biophys. Acta. 2017; pii: S0167-4889(17)30161-1. doi: 10.1016/j.bbamcr.2017.06.009. [Epub ahead of print].
  49. McCawley L.J., Matrisian L.M. Matrix metalloproteinases: they’re not just for matrix anymore! // Curr. Opin. Cell. Biol. 2001. V. 13. № 5. Р. 534–540.
  50. Gershtejn E.S., Mushtenko V.V., Korotkova E.A., Bezhanova S.D., Morozov A.A., Alferov A.A., Kazanceva I.A., Kushlinskij N.E. Matriksnye metalloproteina-zy-2, 7, 8, 9 i ih tkanevoj ingibitor 1-go tipa v syvorotke krovi bol'nyh rakom pochki: kliniko-morfologicheskie korrelyacii // Al'manah klinicheskoj mediciny. 2017. T. 45. № 2. S. 94–101.
  51. Gershtejn E.S., Ognerubov N.A., Kushlinskij N.E. Associirovannye s opuhol'yu proteazy i ih tkanevye ingibitory. V kn.: «Biologicheskie markery opuholej: fundamental'nye i klinicheskie issledovaniya» / Pod red. N.E. Kushlinskogo i M.A. Krasil'nikova. M.: Izd-vo RAMN. 2017. S. 197–230.
  52. Cheng Z., Limbu M., Wang Z., Liu J., Liu L., Zhang X., Chen P., Liu B. MMP-2 and 9 in Chronic Kidney Disease // Int. J. Mol. Sci. 2017. V. 18. № 4:pii E776. doi:10.3390/ijms18040776.
  53. Freitas-Rodríguez S., Folgueras A.R., López-Otín C. The role of matrix metalloproteinases in aging: Tissue remodeling and beyond // Biochim. Biophys. Acta. 2017; pii: S0167-4889(17)30118-0. doi: 10.1016/j.bbamcr.2017.05.007. [Epub ahead of print].
  54. Gershtejn E.S., Lyovkina N.V., Tereshkina I.V., Ermilova V.D., Kushlinskij D.N., Kryuk YU.V., Kuznecova O.M., Adamyan L.V., Laktionov K.P. Klinicheskie perspektivy issledovaniya matriksnyh metalloproteinaz i ih tkanevyh ingibitorov u bol'nyh rakom yaichnikov // Voprosy biologicheskoj, medicinskoj i farmacevticheskoj himii. 2011. № 10. S. 27–34.
  55. Ivannikov A.A., CHang V.L., Gershtejn E.S., Stilidi I.S., Ognerubov N.A., Kush-linskij N.E. Matriksnye metalloproteinazy i ih tkanevoj ingibitor 2 tipa v plazme krovi pervichnyh bol'nyh rakom zheludka: klinicheskij analiz // Vestnik Tambovskogo universiteta. 2014. T. 19. Vyp. 6. S. 1928–1933.
  56. Kushlinskij N.E., Babkina I.V., Kuznecov I.N., Korotkova E.A., Ten E.A., Buly-cheva I.V., Solov'ev YU.N., Aliev M.D. Associirovannye s opuhol'yu matriksnye metalloproteinazy v syvorotke krovi bol'nyh pervichnymi sarkomami kostej // Molekulyarnaya medicina. 2014. № 1. S. 43–46.
  57. Bui T., Hoang A., Le P., Pham B., Nguyen L.T.T., Do H.M., Ta T.V., Trinh T.H. Matrix metalloproteinases in Vietnamese patients with colorectal cancer // Oncol. Lett. 2017. V. 13. № 4. Р. 2097–2104.
  58. Hieronimus B., Pfohl J., Busch C., Graeve L. Expression and Characterization of Membrane-Type 4 Matrix Metalloproteinase (MT4-MMP) and its Different Forms in Melanoma // Cell. Physiol. Biochem. 2017. V. 42. № 1. Р. 198–210.
  59. Juchniewicz A., Kowalczuk O., Milewski R., Laudanski W., Dziegielewski P., Koz-lowski M., Nikliński J. MMP-10, MMP-7, TIMP-1 and TIMP-2 mRNA expression in esophageal cancer // Acta. Biochim. Pol. 2017. V. 64. № 2. Р. 295–299.
  60. Merchant N., Nagaraju G.P., Rajitha B., Lammata S., Jella K.K., Buchwald Z.S., Lakka S.S., Ali A.N. Matrix metalloproteinases: their functional role in lung cancer // Carcino-genesis. 2017. doi:10.1093/carcin/bgx063.
  61. Miao C., Liang C., Zhu J., Xu A., Zhao K., Hua Y., Zhang J., Chen W., Suo C., Zhang C., Liu Y., Su S., Wang Z. Prognostic role of matrix metalloproteinases in bladder carcinoma: a systematic review and meta-analysis // Oncotarget. 2017. V. 8. № 19. Р. 32309–32321.
  62. Inoue Y., Abe K., Obata K., Yoshioka T., Ohmura G., Doh K., Yamamoto K., Hoshiai H., Noda K. Immunohistochemical studies on matrix metalloproteinase-9 (MMP-9) and type-IV collagen in endometrial carcinoma // J. Obstet. Gynaecol. Res. 1997. V. 23. № 2. Р. 139–145.
  63. Iurlaro M., Loverro G., Vacca A., Cormio G., Ribatti D., Minischetti M., Ria R., Bruno M., Selvaggi L. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with upgrading and myometrial invasion in endometrial carcinoma // Eur. J. Clin. Invest. 1999. V. 29. № 9. Р. 793–801.
  64. Moser P.L., Hefler L., Tempfer C., Neunteufel W., Kieback D.G., Gitsch G. Immuno-histochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer // Anticancer Res. 1999. V. 19. № 3B. Р. 2365–2367.
  65. Ueno H., Yamashita K., Azumano I., Inoue M., Okada Y. Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in human endometrial carcinomas // Int. J. Cancer. 1999. V. 84. № 5. Р. 470–477.
  66. Tunuguntla R., Ripley D., Sang Q.X., Chegini N. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinases TIMP-3 and -4 in benign endometrium and endometrial cancer // Gynecol. Oncol. 2003. V. 89. № 3. Р. 453–459.
  67. Erdemoglu E., Güney M., Karahan N., Mungan T. Immunohistochemical expression of MMP-2, MMP-9 and COX-2 in Stage IA malignant polyps of the endometrium // Eur. J. Gynaecol. Oncol. 2008. V. 29. № 5. Р. 444–449.
  68. Osteen K.G., Yeaman G.R., Bruner-Tran K.L. Matrix metalloproteinases and endometriosis // Semin. Reprod. Med. 2003. V. 21. № 2. Р. 155–164.
  69. Shaco-Levy R., Sharabi S., Piura B., Sion-Vardy N. MMP-2, TIMP-1, E-cadherin, and beta-catenin expression in endometrial serous carcinoma compared with low-grade endometrial endometrioid carcinoma and proliferative endometrium // Acta. Obstet. Gyne-col. Scand. 2008. V. 87. № 8. Р. 868–874.
  70. Shaco-Levy R., Sharabi S., Benharroch D., Piura B., Sion-Vardy N. Matrix metalloproteinases 2 and 9, E-cadherin, and beta-catenin expression in endometriosis, low-grade endometrial carcinoma and non-neoplastic eutopic endometrium // Eur. J. Obstet. Gynecol. Reprod. Biol. 2008a. V. 139. № 2. Р. 226–232.
  71. Weigel M.T., Kramer J., Schem C., Wenners A., Alkatout I., Jonat W., Maass N., Mundhenke C. Differential expression of MMP-2, MMP-9 and PCNA in endometriosis and endometrial carcinoma // Eur. J. Obstet. Gynecol. Reprod. Biol. 2012. V. 160. № 1. Р. 74–78.
  72. Yang W.W., Hong L., Xu X.X., Wang Q., Huang J.L., Jiang L. Regulation of miR-33b on endometriosis and expression of related factors // Eur. Rev. Med. Pharmacol. Sci. 2017. V. 21. № 9. Р. 2027–2033.
  73. Kelly R.W., King A.E., Critchley H.O. Cytokine control in human endometrium // Reproduction. 2001. V. 121. № 1. Р. 3–19.
  74. Gaide Chevronnay H.P., Selvais C., Emonard H., Galant C., Marbaix E., Henriet P. Regulation of matrix metalloproteinases activity studied in human endometrium as a paradigm of cyclic tissue breakdown and regeneration // Biochim. Biophys. Acta. 2012. V. 1824. № 1. Р. 146–156.
  75. Rodgers W.H., Matrisian L.M., Giudice L.C., Dsupin B., Cannon P., Svitek C., Gorstein F., Osteen K.G. Patterns of matrix metalloproteinase expression in cycling endometrium imply differential functions and regulation by steroid hormones // J. Clin. Invest. 1994. V. 94. № 3. Р. 946–953.
  76. Skinner J.L., Riley S.C., Gebbie A.E., Glasier A.F., Critchley H.O. Regulation of matrix metalloproteinase-9 in endometrium during the menstrual cycle and following administration of intrauterine levonorgestrel // Hum. Reprod. 1999. V. 14. № 3. Р. 793–799.
  77. Marbaix E., Vekemans M., Galant C., Rigot V., Lemoine P., Dubois D., Picquet C., Henriet P., Twagirayezu P., Sufi S. et al. Circulating sex hormones and endometrial stromelysin-1 (matrix metalloproteinase-3) at the start of bleeding episodes in levonorgestrel-implant users // Hum. Reprod. 2000. V. 15(Suppl 3). Р. 120–134.
  78. Singer C.F., Marbaix E., Kokorine I., Lemoine P., Donnez J., Eeckhout Y., Courtoy P.J. The matrix metalloproteinase-1 (MMP-1) expression in the human endometrium is inversely regulated by interleukin-1 alpha and sex steroids // Ceska Gynekol. 2000. V. 65. № 4. Р. 211–215.
  79. Vincent A.J., Salamonsen L.A. The role of matrix metalloproteinases and leukocytes in abnormal uterine bleeding associated with progestin-only contraceptives // Hum. Reprod. 2000. № 15(Suppl. 3). Р.135–143.
  80. Vincent A.J., Zhang J., Ostor A., Rogers P.A., Affandi B., Kovacs G., Salamonsen L.A. Matrix metalloproteinase-1 and -3 and mast cells are present in the endometrium of women using progestin-only contraceptives // Hum. Reprod. 2000. V. 15. № 1. Р. 123–130.
  81. Zhang X., Nothnick W.B. The role and regulation of the uterine matrix metalloproteinase system in menstruating and non-menstruating species // Front. Biosci. 2005. № 10. Р. 353–366.
  82. Koks C.A., Groothuis P.G., Slaats P., Dunselman G.A., de Goeij A.F., Evers J.L. Matrix metalloproteinases and their tissue inhibitors in antegradely shed menstruum and peritoneal fluid // Fertil. Steril. 2000. V. 73. № 3. Р. 604–612.
  83. Goffin F., Munaut C., Frankenne F., Perrier D'Hauterive S., Beliard A., Fridman V., Nervo P., Colige A., Foidart J.M. Expression pattern of metalloproteinases and tissue inhibitors of matrix metalloproteinases in cycling human endometrium // Biol. Reprod. 2003. V. 69. № 3. Р. 976–984.
  84. Galant C., Vekemans M., Lemoine P., Kokorine I., Twagirayezu P., Henriet P., Picquet C., Rigot V., Eeckhout Y., Courtoy P.J. et al. Temporal and spatial association of matrix metalloproteinases with focal endometrial breakdown and bleeding upon progestin-only contraception // J. Clin. Endocrinol. Metab. 2000. V. 85. № 12. Р. 4827–4834.
  85. Di Nezza L.A., Jobling T., Salamonsen L.A. Progestin suppresses matrix metalloproteinase production in endometrial cancer // Gynecol. Oncol. 2003. V. 89. № 2. Р. 325–333.
  86. Park H.I., Ni J., Gerkema F.E., Liu D., Belozerov V.E., Sang Q.X. Identification and characterization of human endometase (Matrix metalloproteinase-26) from endometrial tumor // J. Biol. Chem. 2000. V. 275. № 27. Р. 20540–20544.
  87. Chegini N., Rhoton-Vlasak A., Williams R.S. Expression of matrix metalloproteinase-26 and tissue inhibitor of matrix metalloproteinase-3 and -4 in endometrium throughout the normal menstrual cycle and alteration in users of levonorgestrel implants who experience irregular uterine bleeding // Fertil. Steril. 2003. V. 80. № 3. Р. 564–570.
  88. Isaka K., Nishi H., Nakai H., Nakada T., Feng Li Y., Ebihara Y., Takayama M. Matrix metalloproteinase-26 is expressed in human endometrium but not in endometrial carcinoma // Cancer. 2003. V. 97. № 1. Р. 79–89.
  89. Pilka R., Norata G.D., Domanski H., Andersson C., Hansson S., Eriksson P., Casslen B. Matrix metalloproteinase-26 (matrilysin-2) expression is high in endometrial hyperplasia and decreases with loss of histological differentiation in endometrial cancer // Gynecol. Oncol. 2004. V. 94. № 3. Р. 661–670.
  90. Nishi H., Kuroda M., Isaka K. Estrogen and estrogen receptor induce matrix metalloprotei¬nase-26 expression in endometrial carcinoma cells // Oncol. Rep. 2013. V. 30. № 2. Р. 751–756.
  91. Markova I., Duskova M., Lubusky M., Kudela M., Zapletalova J., Prochazka M., Pilka R. Selected immunohistochemical prognostic factors in endometrial cancer // Int. J. Gynecol. Cancer. 2010. V. 20. № 4. Р. 576–582.
  92. Krasnopol'skij V.I., Buyanova S.N., Shchukina N.A., Popov A.A. Operativnaya ginekologiya. Izd. 2-e, pererab. M.: MEDpress-informb 2013. 320 s.
  93. Zhou H.E., Nothnick W.B. The relevancy of the matrix metalloproteinase system to the pathophysiology of endometriosis // Front. Biosci. 2005. № 10. Р. 569–575.
  94. Kim H.O., Yang K.M., Kang I.S., Koong M.K., Kim H.S., Zhang X., Kim I. Expression of CD44s, vascular endothelial growth factor, matrix metalloproteinase-2 and Ki-67 in peritoneal, rectovaginal and ovarian endometriosis // J. Reprod. Med. 2007. V. 52. № 3. Р. 207–213.
  95. Matsuzaki S., Maleysson E., Darcha C. Analysis of matrix metalloproteinase-7 expression in eutopic and ectopic endometrium samples from patients with different forms of endometriosis // Hum. Reprod. 2010. V. 25. № 3. Р. 742–750.

© Издательство «РАДИОТЕХНИКА», 2004-2017            Тел.: (495) 625-9241                   Designed by [SWAP]Studio